NCT06261060招募中2 期
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Safety and adverse events (AEs)
研究概览
简要总结
To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
详细描述
Primary Objective:
• Evaluate the safety and tolerability of low-dose sirolimus in participants with RUNX1 familial platelet disorder (RUNX1-FPD)
Secondary Objectives:
- Evaluate increases in platelet counts during and after treatment with low-dose sirolimus
- Evaluate changes in somatic mutation variant allele frequency (VAF)
- Monitor the rate of somatic mutation acquisition (ie, mutation burden)
- Assess change in platelet aggregation score
- Measure the change from baseline in bleeding score (ISTH-BAT)
- Evaluate change in mTORC1 downstream signaling (pS6/EBP)
Exploratory Objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants has provided signed, informed consent before initiation of any study specific procedures
- •Aged ≥18 years at the time of signing the informed consent
- •Confirmed P/LP germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules80
- •Participants must be willing to provide bone marrow sample at time of screening and at the end of treatment with sirolimus
- •Platelet count of ≥50,000/µL
- •Adequate renal function: estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation, >30 mL/min/1.73m2
- •Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 × upper limit of normal (ULN) and total bilirubin <1.5 × ULN
- •Adequate cardiac function: left ventricular ejection fraction >50%
排除标准
- •Known allergy to sirolimus
- •History of lymphoma or other hematologic malignancies
- •Uncontrolled bleeding
- •Any prior diagnosis of myelodysplastic syndrome or other hematologic malignancy using International Working Group criteria
- •Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1
- •Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (eg, rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (eg, bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors [eg, ritonavir, indinavir, boceprevir, and telaprevir], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (eg, carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort [Hypericum perforatum]), or drugs with blood concentrations that could increase (eg, verapamil) within 7 days before study day 1
- •Use of cannabidiol, which can increase blood levels of sirolimus, within 7 days before study day 1
- •Myocardial infarction within 6 months before study day 1, congestive heart failure (New York Heart Association > class II)
- •Total cholesterol >300 mg/dL or triglyceride >400 mg/dL
- •Arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before study day 1
- •Infection requiring intravenous anti-infective treatment within 1 week of study day 1
- •Live vaccines (eg, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid) within 28 days before study day 1
- •Known diagnosis of chronic viral infection (eg, hepatitis B or C or HIV, and Epstein-Barr) or tuberculosis
- •Women who are pregnant, may become pregnant, or who are breastfeeding
研究组 & 干预措施
Arm 1
Experimental
Participants will visit the study clinic 2 times during Week 1, one (1) time during Weeks 2-4, and then 1 time every 2 weeks after that (Weeks 6, 8, 10, and so on) until Week 22 (Month 6). Then participants will have a follow-up visit at Week 24 and again at Week 52 (Month 12). Participants will take sirolimus by mouth every day, at about the same time each day. Swallow the tablet(s) whole with a full glass of water (about 1 cup). Do not crush or chew the tablet(s). Participants may take sirolimus with or without food.
干预措施: Sirolimus (Drug)
结局指标
主要结局
Safety and adverse events (AEs)
时间窗: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX)Coronary Artery DiseaseNCT00233766Cordis US Corp.60
Unknown
4 期
Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney TransplantKidney TransplantationNCT02208791University of Sao Paulo General Hospital45
已完成
4 期
Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney TransplantKidney TransplantationNCT00188955University of Manitoba40
已完成
2 期
Sirolimus Treatment in Hospitalized Patients With COVID-19 PneumoniaCOVID-19NCT04341675University of Cincinnati32
招募中
2 期
Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous MalformationsArteriovenous MalformationsNCT02042326Centre Hospitalier Universitaire, Amiens50